InvestIdeas

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

These biotech ETFs are flourishing this year and some could be future winners with or without Covid-19.

By Todd Shriber

1. SPDR S&P Biotech ETF (NYSEARCA:XBI)
2. ARK Genomic Revolution ETF (CBOE:ARKG)
3. ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)
4. Principal Healthcare Innovators Index ETF (NASDAQ:BTEC)
5. First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT)
6. Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR)
7. ETFMG Treatments, Testing and Advancements ETF (NYSEARCA:GERM)

Source: InvestorPlace

https://investorplace.com/2020/08/7-bio ... h=nonbuyer

vested IBB

Is Bio-Tech Creating Head-And-Shoulders Topping Pattern?

By Chris Kimble

Biotech ETF (NASDAQ:IBB) has performed better than the S&P 500, by nearly 9% this year, which sends a short-term bullish message.

The same positive performance message cannot be said for IBB over the past five years, as it lags the S&P 500 by more than 50% since the 2011 highs.

Is this long-term underperformance for Biotech stocks about to come to an end? We should find out very soon.

IBB is currently testing 2011 highs over the past four months, where it is possible it is creating a short-term “head-and-shoulders” topping pattern.

What would IBB have to do to eliminate the potential topping pattern? A close above $150 would end this pattern and suggest that is 2020 relative strength will continue.

Keep a close eye on IBB over the next few weeks, as its price action should send an important short and long-term price message.

Source: investing.com

https://www.investing.com/analysis/is-b ... -200537777

These Stocks Are Offering a Prime Entry Point

by Jody Chudley

The first reason is there’s uncertainty as to whether the Biden administration will be tougher on pharmaceutical mergers.

The second reason biotech stocks have been demolished is momentum.

XBI: Equal-weighted ETFs are therefore much more diversified than market-capitalization-weighted ETFs, which are top-heavy toward the bigger companies.

Source: Wealthy Retirement

https://dailytradealert.com/2022/02/14/ ... try-point/

Why US biotech stocks are looking healthier after a tough year

Headwinds are starting to abate with a permanent FDA commissioner installed, uncertainty around drug-pricing reform set to ease and a cash-rich biopharma industry eyeing up biotech’s low valuations

by Andy Acker

Source: SCMP

https://www.scmp.com/comment/opinion/ar ... tough-year

not vested

The XBI Biotech ETF Has Bottomed for Now: How I'd Play It

By BRUCE KAMICH

Source: Real Money

https://realmoney.thestreet.com/investi ... BPlay%2BIt

Chinese biopharma stocks slump after Biden targets sector with executive order, opens new front in tensions with Beijing

by Zhang Shidong

Source: SCMP

https://www.scmp.com/business/china-bus ... ets-sector

Chinese pharmaceutical firms’ US expansion plans to come up against brick wall of greater regulatory scrutiny

Chinese pharmaceutical companies, biotech firms in particular, will face rising regulatory hurdles in conducting acquisitions in the US, Fitch analyst says

Expansion by Chinese contract development and manufacturing organisations could be affected by new executive order, Simon-Kucher and Partners executive says

by Peggy Sito

Source: SCMP

https://www.scmp.com/business/china-bus ... plans-come

This Sector Could Rally in 2024

by Chris Igou

Source: Daily Wealth

https://tradesoftheday.com/2023/12/08/t ... y-in-2024/

If These Boom-and-Bust Stocks Rally Further From Here, Major Outperformance is Likely

by Brett Eversole

Two scenarios are possible from here… Either biotech stocks will reverse back to the pain we saw for most of 2023, or they’ll absolutely soar in the months ahead.

We’ll be watching this sector closely. If it rallies further from here, major outperformance is likely… So if prices keep rising, consider adding biotech to your portfolio.

Source: DailyWealth.com

https://dailytradealert.com/2024/02/07/ ... Wealth.com

These Stocks Are Poised to Take Off in the Years to Come

by Dr. David Eifrig

The SPDR S&P Biotech Fund (XBI) has risen almost 30% over the past four months.

XBI is still well off its 2021 highs. But it’s encouraging to see investors beginning to regain interest.

Health care and biotech stocks are poised to take off in the years to come, thanks to new technologies and medicines. So if you haven’t already, consider gaining some exposure to this sector today.

Source: DailyWealth.com

https://dailytradealert.com/2024/03/21/ ... s-to-come/